Mark Cassidy, President & CEO, Aji Bio-Pharma Europe
More Content From Mark Cassidy, President & CEO, Aji Bio-Pharma Europe
-
Working with Lipid Nanoparticle Based Drugs (LNPs) and Other Complex Formulations
If you are considering an LNP-based formulation or another complex drug, here are several points to consider to make the process more efficient.Infographics Released on 02.29.2024
-
How To Select The Ideal HPAPI Manufacturing Partner
To ensure safety during HPAPI production, manufacturers must have the knowledge to effectively use containment and design high-quality equipment.White Papers / Tech Papers Released on 02.29.2024
-
To GMP Or Not To GMP? That Is The (Plasmid) Question
How can you maintain a manageable budget while procuring a high-quality plasmid supply?White Papers / Tech Papers Released on 02.29.2024
-
Aji Bio-Pharma Corporate Brochure
As a member of the Ajinomoto Group, we offer an extensive global reach with facilities in Belgium, United States, Japan, and India.Literature / Brochures Released on 02.29.2024
-
Leveraging CDMO's in Pharma's Drive Towards Net Zero
The push to reduce carbon emissions across some of the most energy-intensive industries has created new complexities for many companies.Sponsored Content Released on 04.19.2023
-
Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics
After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene.White Papers / Tech Papers Released on 03.14.2023
-
MAY THE FLOW BE WITH YOU: CONTINUOUS FLOW MANUFACTURING OF PHARMACEUTICAL INGREDIENTS
A clear increase in continuous flow processes has emerged over the past decade.White Papers / Tech Papers Released on 12.19.2019
-
Simplifying Recombinant Protein Production: Breaking Down the Corynex Protein Expression System
The rise of biologics is having a dramatic impact on how physicians treat many serious and chronic illnesses.White Papers / Tech Papers Released on 08.27.2019
-
5 ADC Manufacturing Challenges You Need To Know
Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.White Papers / Tech Papers Released on 08.27.2019
-
Critical Factors of Fill Finish Manufacturing For Biologics
The bulk drug substance, formulation, and sterile filtering and filling of the final drug product all require special handling procedures.White Papers / Tech Papers Released on 08.27.2019
-
Is Your Complex Formulation Process Set Up for Success?
Often, the implementation of specialized equipment and/or processes is necessary to ensure successful formulation.White Papers / Tech Papers Released on 08.27.2019
-
Preparing for Your CDMO Selection Process
Finding the CDMO that is right for your company and project can be a daunting task, particularly if this is your first time outsourcing.White Papers / Tech Papers Released on 08.27.2019
-
Biologics candidate enters clinical trials for first time using CORYNEX® Protein Expression System
...News Releases Released on 10.04.2016
-
Althea Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies
...News Releases Released on 05.17.2016
